Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly

Leukemia 2026 Open access

Read full text
Authors: Maximilian Merz, Eric Jurgens, David Fandrei, Saad Z. Usmani, Sham Mailankody
DOI: 10.1038/s41375-026-02933-2
Cited by: 3
References: 69

Abstract

More than a decade after the initial clinical reports of chimeric antigen receptor (CAR) T-cell therapy emerging from early-phase trials and individual case studies [ 1 , 2 , 3 ]. CAR T cells directed against B-cell maturation antigen (BCMA) have now evolved into an established standard of care for patients with relapsed or refractory multiple myeloma (RRMM) [ 4 ].

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments T-cell and B-cell Immunology

Publication details

Journal / source
Leukemia
Publisher
Springer Science and Business Media LLC
Volume
40
Issue
5
Pages
872–879
Publication date
31 March 2026
Language
EN